Physician profile
Kazem Hak
NPI 1083688725
$11,866.17
in general payments reported to CMS, 2019-2025
61 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,211 · 2020: $910 · 2021: $1,340 · 2022: $2,123 · 2023: $2,895 · 2024: $2,264 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,271 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,270.66 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,591.18 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,567.73 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Novo Nordisk INC | $1,375.80 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $814.71 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $660.44 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $460.37 | 2019-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $389.49 | 2019-2023 | |
| Pfizer INC. | $346.07 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $321.83 | 2020-2023 | |
| Lilly USA, LLC | $311.89 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $291.64 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.13 | 2019-2024 | Jardiance, Ofev, Stiolto Respimat |
| Axsome Therapeutics, INC. | $246.39 | 2023-2024 | Sunosi, Auvelity |
| Mylan Specialty L.P. | $237.58 | 2019-2024 | Yupelri |
| Collegium Pharmaceutical, INC. | $198.19 | 2022-2024 | Belbuca |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kazem Hak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.